Kee Kiat Yeo1,2, Ashley S Margol3, Rebekah J Kennedy1, Long Hung1, Nathan J Robison1, Girish Dhall1,4, Shahab Asgharzadeh1. 1. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, 4650 Sunset Boulevard, MS #54, Los Angeles, CA, 90027-6016, USA. 2. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA. 3. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, 4650 Sunset Boulevard, MS #54, Los Angeles, CA, 90027-6016, USA. amargol@chla.usc.edu. 4. The Alabama Center for Childhood Cancer and Blood Disorders at Children's of Alabama, University of Alabama at Birmingham (UAB), Birmingham, USA.
Abstract
PURPOSE: Irradiation-avoiding strategies have been used with relative success in the treatment of infants and young children with medulloblastoma. While advances in cancer genomics have significantly improved our understanding of the tumor biology of medulloblastoma allowing for improved prognostication and risk-stratification, the molecular subgroup-specific outcomes of infants and young children with medulloblastoma treated with irradiation-avoiding strategies remains unknown. METHODS: Molecular and clinical features of children with medulloblastoma treated with irradiation-avoiding strategies at Children's Hospital Los Angeles were analyzed. Molecular subgrouping of these patients was determined using a 31-gene TaqMan Low Density Array signature. Survival analyses were conducted based on 3 molecular subgroups (SHH, Group 3, and Group 4). RESULTS: Twenty-eight patients with medulloblastoma received irradiation-sparing regimens and were included in this analysis. Patients were divided into SHH (n = 16), Group 3 (n = 3) and Group 4 subgroups (n = 9). Subgroup specific 5-year progression-free and overall survival was 81.2% (95% CI 52.5-93.5) and 93.7% (95% CI 63.2-99.1) for SHH, 0% and 0% for Group 3 and 0% and 44.4% (95% CI 13.6-71.9) for Group 4. CONCLUSION: The majority of young children with SHH-subgroup medulloblastoma can be treated effectively with irradiation-sparing regimens. Our results support the use of chemotherapy-only strategies for upfront treatment of young children with SHH medulloblastoma, while demonstrating the urgent need for intensification/augmentation of treatment for patients with group 3/4 medulloblastoma.
PURPOSE: Irradiation-avoiding strategies have been used with relative success in the treatment of infants and young children with medulloblastoma. While advances in cancer genomics have significantly improved our understanding of the tumor biology of medulloblastoma allowing for improved prognostication and risk-stratification, the molecular subgroup-specific outcomes of infants and young children with medulloblastoma treated with irradiation-avoiding strategies remains unknown. METHODS: Molecular and clinical features of children with medulloblastoma treated with irradiation-avoiding strategies at Children's Hospital Los Angeles were analyzed. Molecular subgrouping of these patients was determined using a 31-gene TaqMan Low Density Array signature. Survival analyses were conducted based on 3 molecular subgroups (SHH, Group 3, and Group 4). RESULTS: Twenty-eight patients with medulloblastoma received irradiation-sparing regimens and were included in this analysis. Patients were divided into SHH (n = 16), Group 3 (n = 3) and Group 4 subgroups (n = 9). Subgroup specific 5-year progression-free and overall survival was 81.2% (95% CI 52.5-93.5) and 93.7% (95% CI 63.2-99.1) for SHH, 0% and 0% for Group 3 and 0% and 44.4% (95% CI 13.6-71.9) for Group 4. CONCLUSION: The majority of young children with SHH-subgroup medulloblastoma can be treated effectively with irradiation-sparing regimens. Our results support the use of chemotherapy-only strategies for upfront treatment of young children with SHH medulloblastoma, while demonstrating the urgent need for intensification/augmentation of treatment for patients with group 3/4 medulloblastoma.
Entities:
Keywords:
Drug therapy; Genomics; Medulloblastoma; Pediatrics; Radiation
Authors: Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316
Authors: Ashley S Margol; Nathan J Robison; Janahan Gnanachandran; Long T Hung; Rebekah J Kennedy; Marzieh Vali; Girish Dhall; Jonathan L Finlay; Anat Erdreich-Epstein; Mark D Krieger; Rachid Drissi; Maryam Fouladi; Floyd H Gilles; Alexander R Judkins; Richard Sposto; Shahab Asgharzadeh Journal: Clin Cancer Res Date: 2014-10-24 Impact factor: 12.531
Authors: Bruce H Cohen; J Russell Geyer; Douglas C Miller; John G Curran; Tianni Zhou; Emi Holmes; Sue Ann Ingles; Ira J Dunkel; Joanne Hilden; Roger J Packer; Ian F Pollack; Amar Gajjar; Jonathan L Finlay Journal: Pediatr Neurol Date: 2015-04-09 Impact factor: 3.372
Authors: Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor Journal: Cancer Cell Date: 2017-06-12 Impact factor: 31.743
Authors: P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: J Russell Geyer; Richard Sposto; Mark Jennings; James M Boyett; Richard A Axtell; David Breiger; Emmett Broxson; Bernadine Donahue; Jonathan L Finlay; Joel W Goldwein; Linda A Heier; Dennis Johnson; Claire Mazewski; Douglas C Miller; Roger Packer; Diane Puccetti; Jerilynn Radcliffe; May Lin Tao; Tania Shiminski-Maher Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Girish Dhall; Howard Grodman; Lingyun Ji; Stephen Sands; Sharon Gardner; Ira J Dunkel; Geoffrey B McCowage; Blanca Diez; Jeffrey C Allen; Anjali Gopalan; Albert S Cornelius; Amanda Termuhlen; Minnie Abromowitch; Richard Sposto; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2008-06 Impact factor: 3.167
Authors: Giles W Robinson; Vasilisa A Rudneva; Ivo Buchhalter; Catherine A Billups; Sebastian M Waszak; Kyle S Smith; Daniel C Bowers; Anne Bendel; Paul G Fisher; Sonia Partap; John R Crawford; Tim Hassall; Daniel J Indelicato; Frederick Boop; Paul Klimo; Noah D Sabin; Zoltan Patay; Thomas E Merchant; Clinton F Stewart; Brent A Orr; Jan O Korbel; David T W Jones; Tanvi Sharma; Peter Lichter; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Richard J Gilbertson; Robert P Sanders; Arzu Onar-Thomas; David W Ellison; Amar Gajjar; Paul A Northcott Journal: Lancet Oncol Date: 2018-05-16 Impact factor: 41.316
Authors: Paul A Northcott; Ivo Buchhalter; A Sorana Morrissy; Volker Hovestadt; Joachim Weischenfeldt; Tobias Ehrenberger; Susanne Gröbner; Maia Segura-Wang; Thomas Zichner; Vasilisa A Rudneva; Hans-Jörg Warnatz; Nikos Sidiropoulos; Aaron H Phillips; Steven Schumacher; Kortine Kleinheinz; Sebastian M Waszak; Serap Erkek; David T W Jones; Barbara C Worst; Marcel Kool; Marc Zapatka; Natalie Jäger; Lukas Chavez; Barbara Hutter; Matthias Bieg; Nagarajan Paramasivam; Michael Heinold; Zuguang Gu; Naveed Ishaque; Christina Jäger-Schmidt; Charles D Imbusch; Alke Jugold; Daniel Hübschmann; Thomas Risch; Vyacheslav Amstislavskiy; Francisco German Rodriguez Gonzalez; Ursula D Weber; Stephan Wolf; Giles W Robinson; Xin Zhou; Gang Wu; David Finkelstein; Yanling Liu; Florence M G Cavalli; Betty Luu; Vijay Ramaswamy; Xiaochong Wu; Jan Koster; Marina Ryzhova; Yoon-Jae Cho; Scott L Pomeroy; Christel Herold-Mende; Martin Schuhmann; Martin Ebinger; Linda M Liau; Jaume Mora; Roger E McLendon; Nada Jabado; Toshihiro Kumabe; Eric Chuah; Yussanne Ma; Richard A Moore; Andrew J Mungall; Karen L Mungall; Nina Thiessen; Kane Tse; Tina Wong; Steven J M Jones; Olaf Witt; Till Milde; Andreas Von Deimling; David Capper; Andrey Korshunov; Marie-Laure Yaspo; Richard Kriwacki; Amar Gajjar; Jinghui Zhang; Rameen Beroukhim; Ernest Fraenkel; Jan O Korbel; Benedikt Brors; Matthias Schlesner; Roland Eils; Marco A Marra; Stefan M Pfister; Michael D Taylor; Peter Lichter Journal: Nature Date: 2017-07-19 Impact factor: 49.962